Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 74.1% in March

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 15,700 shares, a decline of 74.1% from the February 29th total of 60,600 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average daily volume of 136,600 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Virax Biolabs Group

Several hedge funds have recently bought and sold shares of VRAX. Armistice Capital LLC bought a new position in shares of Virax Biolabs Group in the first quarter worth about $1,043,000. Legal & General Group Plc bought a new position in shares of Virax Biolabs Group in the fourth quarter worth about $73,000. Virtu Financial LLC bought a new position in shares of Virax Biolabs Group in the fourth quarter worth about $35,000. Finally, UBS Group AG bought a new position in shares of Virax Biolabs Group in the third quarter worth about $38,000. Institutional investors own 8.61% of the company’s stock.

Virax Biolabs Group Price Performance

NASDAQ:VRAX opened at $0.71 on Thursday. The stock has a 50-day simple moving average of $0.88 and a two-hundred day simple moving average of $1.83. Virax Biolabs Group has a 52-week low of $0.70 and a 52-week high of $8.54.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.